

Michael Fx Gnant

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7660992/michael-fx-gnant-publications-by-citations.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

521 papers	37,830 citations	78 h-index	188 g-index
639 ext. papers	43,978 ext. citations	5.8 avg, IF	6.93 L-index

#	Paper	IF	Citations
521	Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet, The</i> , 2005 , 366, 2087-106	40	3823
520	Tamoxifen for early breast cancer: an overview of the randomised trials. <i>Lancet, The</i> , 1998 , 351, 1451-1467	40	3357
519	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 520-9	59.2	2054
518	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013 , 24, 2206-23	10.3	2048
517	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. <i>Lancet, The</i> , 2014 , 383, 2127-35	40	1237
516	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015 , 26, 1533-46	10.3	1122
515	Breast cancer. <i>Lancet, The</i> , 2017 , 389, 1134-1150	40	923
514	Endocrine therapy plus zoledronic acid in premenopausal breast cancer. <i>New England Journal of Medicine</i> , 2009 , 360, 679-91	59.2	871
513	Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. <i>Lancet, The</i> , 2005 , 366, 455-62	40	734
512	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 66	51.1	698
511	Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. <i>Journal of Clinical Oncology</i> , 2010 , 28, 509-18	2.2	615
510	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017 , 28, 1700-1712	10.3	586
509	A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. <i>Clinical Cancer Research</i> , 2011 , 17, 6012-20	12.9	468
508	Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3859-65	2.2	442
507	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018 , 19, 27-39	21.7	413
506	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. <i>Lancet Oncology, The</i> , 2011 , 12, 631-41	21.7	374
505	Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. <i>Annals of Oncology</i> , 2008 , 19, 420-32	10.3	366

504	Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 <i>Annals of Oncology</i> , 2014 , 25, 2357-2362	10.3	361
503	Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015 , 386, 433-43	4.0	357
502	Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. <i>Advances in Therapy</i> , 2013 , 30, 870-84	4.1	355
501	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 367-377	21.7	339
500	Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1508-16	3.1	329
499	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1688-1700	21.7	328
498	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. <i>Lancet Oncology, The</i> , 2008 , 9, 840-9	21.7	309
497	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019 , 30, 1541-1557	10.3	288
496	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1310-1315	13.4	285
495	Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. <i>Clinical Cancer Research</i> , 2002 , 8, 1831-7	12.9	275
494	Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 820-8	2.2	264
493	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. <i>BMC Medical Genomics</i> , 2015 , 8, 54	3.7	242
492	Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. <i>Annals of Oncology</i> , 2014 , 25, 339-45	10.3	239
491	Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 12. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1614-7	2.2	238
490	Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1845-53	9.7	232
489	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. <i>British Journal of Cancer</i> , 2013 , 109, 2959-64	8.7	229
488	Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. <i>Annals of Oncology</i> , 2015 , 26, 313-20	10.3	205
487	Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. <i>Lancet Oncology, The</i> , 2006 , 7, 991-6	21.7	198

486	Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. <i>Annals of Surgery</i> , 2004 , 240, 306-12	7.8	193
485	TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. <i>Clinical Cancer Research</i> , 2000 , 6, 50-6	12.9	175
484	Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 334-40	10.3	171
483	Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2653-9	12.2	161
482	Effects of bone-targeted agents on cancer progression and mortality. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1059-67	9.7	157
481	St. Gallen 2011: Summary of the Consensus Discussion. <i>Breast Care</i> , 2011 , 6, 136-141	2.4	156
480	Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. <i>Journal of Clinical Oncology</i> , 2015 , 33, 916-22	2.2	152
479	The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 1298-305	12.9	144
478	Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 1807-1815	4.0	141
477	Third consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2009 , 20, 1771-85	10.3	139
476	Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. <i>Annals of Oncology</i> , 2011 , 22, 2546-2555	10.3	139
475	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	4.0	137
474	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. <i>Annals of Oncology</i> , 2013 , 24, 640-7	10.3	137
473	Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2000-12	15.9	137
472	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. <i>Annals of Oncology</i> , 2016 , 27, 379-90	10.3	135
471	Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. <i>Cancer Treatment Reviews</i> , 2012 , 38, 407-15	14.4	133
470	Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. <i>Cancer Gene Therapy</i> , 2000 , 7, 66-73	5.4	133
469	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. <i>Journal of Bone Oncology</i> , 2017 , 7, 1-12	4.5	127

468	Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. <i>International Journal of Cancer</i> , 2003 , 104, 677-82	7.5	125
467	Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3853-8	2.2	123
466	Outcomes of surgical, percutaneous endoscopic, and percutaneous radiologic gastrostomies. <i>Archives of Surgery</i> , 1998 , 133, 1076-83		122
465	VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. <i>Surgery</i> , 2006 , 139, 839-46	3.6	121
464	Stereotactic 11-gauge vacuum-assisted breast biopsy: a validation study. <i>American Journal of Roentgenology</i> , 2002 , 179, 1503-7	5.4	117
463	The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. <i>Journal of Surgical Research</i> , 2000 , 91, 26-31	2.5	113
462	Dendritic cell-based vaccination in solid cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 135-42	2.2	112
461	Impact of pretreatment thrombocytosis on survival in primary breast cancer. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 1098-1106	7	107
460	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSC-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 339-351	21.7	106
459	Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. <i>Clinical Cancer Research</i> , 2001 , 7, 1669-75	12.9	105
458	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. <i>Annals of Oncology</i> , 2014 , 25, 808-815	10.3	103
457	Toward a Consensus on Centralization in Surgery. <i>Annals of Surgery</i> , 2018 , 268, 712-724	7.8	97
456	CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSC) 8. <i>Clinical Cancer Research</i> , 2013 , 19, 500-7	12.9	94
455	Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). <i>Annals of Oncology</i> , 2017 , 28, v605	10.3	92
454	Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013 , 13, 421-432.e8	3	89
453	St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. <i>Breast Care</i> , 2017 , 12, 102-107	2.4	87
452	Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 99, 135-41	4.4	87
451	Activity of T-DM1 in Her2-positive breast cancer brain metastases. <i>Clinical and Experimental Metastasis</i> , 2015 , 32, 729-37	4.7	85

450	St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. <i>Breast Care</i> , 2019 , 14, 103-110	2.4	84
449	St. Gallen 2013: brief preliminary summary of the consensus discussion. <i>Breast Care</i> , 2013 , 8, 102-9	2.4	84
448	NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. <i>Surgery</i> , 2011 , 149, 311-20	3.6	83
447	Second consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2007 , 18, 215-25	3.3	83
446	Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. <i>Human Gene Therapy</i> , 1999 , 10, 649-57	4.8	79
445	Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. <i>Annals of Oncology</i> , 2015 , 26, 1485-91	10.3	78
444	Bisphosphonates in the adjuvant treatment of early breast cancer. <i>Breast Cancer Research</i> , 2009 , 11,	8.3	78
443	Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. <i>Clinical Breast Cancer</i> , 2002 , 3, 65-72	3	78
442	Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 654-63	9.7	77
441	Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2012-8	2.2	77
440	Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 237-44	4.4	76
439	The use of a breast symmetry index for objective evaluation of breast cosmesis. <i>Breast</i> , 2007 , 16, 429-35	3.6	74
438	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020 , 5,	6	74
437	Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 722-8	2.2	73
436	Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. <i>Clinical Cancer Research</i> , 2008 , 14, 1767-74	12.9	73
435	A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. <i>British Journal of Cancer</i> , 2007 , 97, 1021-7	8.7	73
434	Do we need HER-2/neu testing for all patients with primary breast carcinoma?. <i>Cancer</i> , 2003 , 98, 2547-53	3.4	72
433	Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. <i>Cancer</i> , 2013 , 119, 1908-15	6.4	70

432	p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. <i>European Journal of Cancer</i> , 1997 , 33, 39-44	7.5	69
431	The AURORA initiative for metastatic breast cancer. <i>British Journal of Cancer</i> , 2014 , 111, 1881-7	8.7	68
430	Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?. <i>Cancer Treatment Reviews</i> , 2012 , 38, 798-806	14.4	67
429	Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer. <i>European Journal of Surgical Oncology</i> , 2009 , 35, 264-70	3.6	64
428	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology, The</i> , 2021 , 22, 212-222	21.7	64
427	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1811-1818	2.2	63
426	Brain metastases free survival differs between breast cancer subtypes. <i>British Journal of Cancer</i> , 2012 , 106, 440-6	8.7	62
425	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 127-138	21.7	62
424	St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. <i>Breast Care</i> , 2015 , 10, 124-30	2.4	61
423	Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial. <i>Radiotherapy and Oncology</i> , 2012 , 102, 10-3	5.3	60
422	Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. <i>British Journal of Cancer</i> , 2012 , 106, 25-31	8.7	60
421	Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIME Trial. <i>Annals of Surgery</i> , 2019 , 269, 1163-1169	7.8	59
420	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1888-1896	27.4	58
419	Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. <i>Oncologist</i> , 2013 , 18, 353-61	5.7	57
418	Potential anticancer properties of bisphosphonates. <i>Seminars in Oncology</i> , 2010 , 37 Suppl 1, S53-65	5.5	57
417	The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. <i>British Journal of Cancer</i> , 2015 , 112, 1405-10	8.7	56
416	Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography. <i>Radiology</i> , 1997 , 202, 421-9	20.5	56
415	Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. <i>Journal of Gastrointestinal Surgery</i> , 2020 , 24, 610-618	3.3	56

414	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1226-1238	21.7	55
413	Evaluation of needle size for breast biopsy: comparison of 14-, 16-, and 18-gauge biopsy needles. <i>American Journal of Roentgenology</i> , 1998 , 171, 59-63	5.4	54
412	Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. <i>Endocrine-Related Cancer</i> , 2003 , 10, 91-8	5.7	53
411	Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver?. <i>Transplantation Proceedings</i> , 1991 , 23, 1567-8	1.1	53
410	Multidetector CT of pancreas: effects of contrast material flow rate and individualized scan delay on enhancement of pancreas and tumor contrast. <i>Radiology</i> , 2006 , 241, 441-8	20.5	52
409	Dendritic cell vaccination in medullary thyroid carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 2944-53	12.9	52
408	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021 , 21, 80-91.e7	3	52
407	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019 , 25, 2975-2987	12.9	51
406	Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). <i>Annals of Oncology</i> , 2014 , 25, 366-71	10.3	51
405	The sequential use of endocrine treatment for advanced breast cancer: where are we?. <i>Annals of Oncology</i> , 2012 , 23, 1378-86	10.3	51
404	Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 82, 207-13	4.4	49
403	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. <i>European Journal of Cancer</i> , 2013 , 49, 2621-32	7.5	48
402	It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998 , 50, 37-46	4.4	48
401	Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?. <i>American Journal of Transplantation</i> , 2005 , 5, 788-94	8.7	48
400	Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. <i>Breast Cancer Research and Treatment</i> , 1994 , 32, 165-75	4.4	48
399	Overexpression of the human homologue for <i>Caenorhabditis elegans</i> cul-4 gene is associated with poor outcome in node-negative breast cancer. <i>Anticancer Research</i> , 2007 , 27, 949-52	2.3	48
398	Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 277-85	4.6	47
397	Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). <i>Journal of Clinical Oncology</i> , 2005 , 23, 527-527	2.2	47

396	Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. <i>Journal of Clinical Oncology</i> , 2003 , 21, 984-90	2.2	46
395	Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. <i>Breast Cancer Research and Treatment</i> , 2001 , 67, 1-8	4.4	46
394	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 523-537	4.4	46
393	NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. <i>World Journal of Surgery</i> , 2011 , 35, 1580-9	3.3	45
392	Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1809-19	15.4	44
391	Aetiology and surgical management of toxic megacolon. <i>Colorectal Disease</i> , 2006 , 8, 195-201	2.1	44
390	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44
389	Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. <i>British Journal of Cancer</i> , 2013 , 108, 2259-63	8.7	43
388	The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. <i>British Journal of Cancer</i> , 2013 , 109, 589-96	8.7	43
387	Exact log-rank tests for unequal follow-up. <i>Biometrics</i> , 2003 , 59, 1151-7	1.8	43
386	Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis. <i>Annals of Surgery</i> , 2018 , 268, 894-902	7.8	43
385	HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. <i>Annals of Oncology</i> , 2010 , 21, 955-60	10.3	42
384	Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. <i>Current Cancer Drug Targets</i> , 2009 , 9, 824-33	2.8	42
383	Future Directions in the Treatment of Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 117-118	4.4	42
382	Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12.. <i>Journal of Clinical Oncology</i> , 2008 , 26, LBA4-LBA4	2.2	42
381	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. <i>Breast</i> , 2014 , 23, 637-43	3.6	41
380	Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). <i>Annals of Surgical Oncology</i> , 2012 , 19, 1808-17	3.1	41
379	Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. <i>Trials</i> , 2018 , 19, 667	2.8	41

378	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 377-386	4.4	39
377	Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2012 , 48, 1932-8	7.5	39
376	Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. <i>Cytokine</i> , 2000 , 12, 339-47	4	39
375	Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II). <i>Cytokine</i> , 2000 , 12, 992-1000	4	39
374	Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancer. <i>British Journal of Cancer</i> , 1995 , 72, 51-5	8.7	39
373	Breast-conserving therapy for centrally located breast cancer. <i>Annals of Surgery</i> , 2008 , 247, 470-6	7.8	38
372	Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 903-10	3.5	38
371	Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2006 , 97, 9-15	4.4	38
370	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 316-324	4	37
369	Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. <i>Oncology Reports</i> , 2009 , 21, 1585-92	3.5	37
368	Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epirubicin and docetaxel + G-CSF. <i>Breast Cancer Research and Treatment</i> , 2007 , 104, 109-14	4.4	37
367	The importance of the effect of underlying disease on rejection outcomes following orthotopic liver transplantation. <i>Transplantation</i> , 1996 , 61, 554-60	1.8	37
366	Prediction of Distant Recurrence Using EndoPredict Among Women with ER, HER2 Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019 , 25, 3865-3872	12.9	36
365	Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 87, 101-11	7	36
364	The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2-early breast cancer. <i>British Journal of Cancer</i> , 2014 , 111, 837-42	8.7	36
363	Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: a prospective randomized study. <i>World Journal of Surgery</i> , 2014 , 38, 465-75	3.3	36
362	An oncoplastic procedure for central and medio-cranial breast cancer. <i>European Journal of Surgical Oncology</i> , 2007 , 33, 1158-63	3.6	36
361	High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. <i>European Journal of Surgical Oncology</i> , 2004 , 30, 243-7	3.6	36

360	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1518-1530	2.2	35
359	The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. <i>Breast</i> , 2014 , 23, 393-9	3.6	34
358	Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts. <i>Disease Markers</i> , 2011 , 31, 55-65	3.2	33
357	Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2004 , 116, 26-31	2.3	33
356	Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal women. <i>International Journal of Cancer</i> , 1992 , 52, 707-12	7.5	33
355	Fighting overtreatment in adjuvant breast cancer therapy. <i>Lancet, The</i> , 2009 , 374, 2029-2030	4.0	32
354	Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 203-13	4.4	32
353	Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials 2013 ,		32
352	In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). <i>Cancer Research</i> , 1999 , 59, 205-12	10.1	32
351	Consensus on Medical Treatment of Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 1-7	4.4	31
350	TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients. <i>EBioMedicine</i> , 2015 , 2, 825-30	8.8	30
349	Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. <i>European Journal of Cancer</i> , 2005 , 41, 2655-61	7.5	30
348	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2001 , 85, 1850-2	8.7	30
347	Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. <i>Annals of Surgery</i> , 1999 , 230, 352-60; discussion 360-1	7.8	30
346	Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo Classification. <i>International Journal of Surgery</i> , 2014 , 12, 334-9	7.5	29
345	The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. <i>Annals of Oncology</i> , 2012 , 23, 2782-2790	10.3	29
344	Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. <i>European Journal of Cancer</i> , 1999 , 35, 398-405	7.5	29
343	St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. <i>Breast Care</i> , 2021 , 16, 135-143	2.4	29

342	Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. <i>British Journal of Cancer</i> , 2013 , 109, 1522-7	8.7	28
341	Breast conservation: evolution of surgical strategies. <i>Breast Journal</i> , 2006 , 12, S165-73	1.2	28
340	Isolated hepatic perfusion for lapine liver metastases: Impact of hyperthermia on permeability of tumor neovasculature. <i>Surgery</i> , 1999 , 126, 890-899	3.6	27
339	Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1481-9	7.5	26
338	Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 286-91	4.6	26
337	Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 121-8	4.4	26
336	Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. <i>British Journal of Cancer</i> , 2010 , 103, 1201-8	8.7	26
335	Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 5888-94 ^{12.9}	12.9	26
334	Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. <i>Clinical Cancer Research</i> , 2008 , 14, 2082-7	12.9	26
333	Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1098-104 ^{5.6}	5.6	26
332	Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1701-9	2.2	26
331	Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2019 , 14, e0215915	3.7	25
330	Role of bisphosphonates in postmenopausal women with breast cancer. <i>Cancer Treatment Reviews</i> , 2014 , 40, 476-84	14.4	24
329	A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. <i>British Journal of Cancer</i> , 2005 , 92, 1655-62	8.7	24
328	Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. <i>Cancer Medicine</i> , 2016 , 5, 2350-8	4.8	24
327	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , 2021 , 22, 1139-1150	21.7	24
326	PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. <i>Oncotmunology</i> , 2018 , 7, e1435226	7.2	23
325	Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4571-7	5.6	23

324	Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. <i>Disease Markers</i> , 2011 , 31, 55-65	3.2	23
323	Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cTNxM0, low rectal cancer: a phase II study. <i>Strahlentherapie Und Onkologie</i> , 2011 , 187, 100-7	4.3	22
322	Zoledronic acid in breast cancer: latest findings and interpretations. <i>Therapeutic Advances in Medical Oncology</i> , 2011 , 3, 293-301	5.4	22
321	Bisphosphonates: prevention of bone metastases in breast cancer. <i>Recent Results in Cancer Research</i> , 2012 , 192, 65-91	1.5	22
320	Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019 , 25, 2737-2744	12.9	22
319	Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. <i>Anticancer Research</i> , 2014 , 34, 6767-73	2.3	22
318	Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy. <i>British Journal of Surgery</i> , 2018 , 105, 811-819	5.3	21
317	Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. <i>British Journal of Cancer</i> , 2013 , 108, 1408-14	8.7	21
316	Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial. <i>European Journal of Cancer</i> , 2011 , 47, 6-7	7.5	21
315	DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised study. <i>European Journal of Cancer</i> , 1992 , 28, 711-6	7.5	21
314	Circulating ICAM-1: novel parameter of renal graft rejection. <i>Transplantation Proceedings</i> , 1993 , 25, 919-20		21
313	S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-ReceptorPositive Early Breast Cancer. 2011 ,		21
312	Adjuvant Bisphosphonates and Breast Cancer Survival. <i>Annual Review of Medicine</i> , 2016 , 67, 1-10	17.4	20
311	BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 771-8	3.5	20
310	Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013 , 29, 1463-73	2.5	20
309	Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3548-51	2.2	20
308	The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 309-16	4.4	20
307	Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group. <i>Annals of Surgery</i> , 2003 , 237, 556-64	7.8	20

306	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 78-86	7.1	20
305	The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. <i>BMC Cancer</i> , 2018 , 18, 1210	4.8	20
304	High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome. <i>Gastroenterology</i> , 2018 , 154, 1543-1545	13.3	19
303	The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. <i>Current Oncology Reports</i> , 2013 , 15, 14-23	6.3	19
302	Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. <i>BMC Cancer</i> , 2009 , 9, 367	4.8	19
301	Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1579-89	3.5	19
300	Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. <i>Clinical Cancer Research</i> , 2007 , 13, 4435-9	12.9	19
299	Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor. <i>Anti-Cancer Drugs</i> , 2002 , 13, 67-74	2.4	19
298	ERR β promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. <i>Oncogene</i> , 2019 , 38, 950-964	9.2	19
297	Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. <i>Pharmacoeconomics</i> , 2015 , 33, 179-90	4.4	18
296	Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. <i>Modern Pathology</i> , 2014 , 27, 906-15	9.8	18
295	New results from the use of bisphosphonates in cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2009 , 3, 213-8	2.6	18
294	Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. <i>Breast Cancer Research and Treatment</i> , 2007 , 103, 45-52	4.4	18
293	P81 Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. <i>Breast</i> , 2005 , 14, S38	3.6	18
292	Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1996 , 111, 827-31; discussion 832	1.5	18
291	Abstract S2-02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial 2016 ,		18
290	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 500-500	2.2	18
289	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. <i>European Journal of Cancer</i> , 2020 , 134, 99-106	7.5	17

288	Knowledge gaps in oncoplastic breast surgery. <i>Lancet Oncology, The</i> , 2020 , 21, e375-e385	21.7	17
287	Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients. <i>Annals of Surgical Oncology</i> , 2012 , 19, 519-26	3.1	16
286	Impact of vesicoureteral reflux on graft survival in renal transplantation. <i>Transplantation Proceedings</i> , 1993 , 25, 1058-9	1.1	16
285	Prognostic impact of breast cancer subtypes in elderly patients. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 91-9	4.4	16
284	Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. <i>Cancer Treatment Reviews</i> , 2012 , 38, 815-24	14.4	15
283	Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer. <i>Breast Journal</i> , 2013 , 19, 149-55	1.2	15
282	Prevention of bone metastases and management of bone health in early breast cancer. <i>Breast Cancer Research</i> , 2010 , 12, 216	8.3	15
281	Phase I/II trial of weekly epirubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 155-9	3.5	15
280	Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSCG) trial 5. <i>European Journal of Cancer</i> , 1999 , 35, S83	7.5	15
279	Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 118, 629-34	4.9	15
278	Haemophilus parainfluenzae liver abscess after successful liver transplantation. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 818-9	9.7	15
277	A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. <i>Anticancer Research</i> , 2014 , 34, 2377-84	2.3	15
276	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 3676-3683	12.9	14
275	Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 421-427	4.4	14
274	Does patient education work in breast cancer? Final results from the global CARIATIDE study. <i>Future Oncology</i> , 2015 , 11, 205-17	3.6	14
273	Objectively measured breast symmetry has no influence on quality of life in breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2012 , 38, 130-6	3.6	14
272	Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. <i>Annals of Oncology</i> , 2008 , 19, 1837-41	10.3	14
271	Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. <i>Cancer</i> , 2003 , 98, 2291-301	6.4	14

270	Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4682-4687	12.9	13
269	Palbociclib for the treatment of postmenopausal breast cancer - an update. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 255-63	4	13
268	1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. <i>European Journal of Cancer</i> , 2014 , 50, S1	7.5	13
267	Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion. <i>Breast Care</i> , 2013 , 8, 293-9	2.4	13
266	Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. <i>Neoplasia</i> , 2011 , 13, 419-27	6.4	13
265	S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. 2011 ,		13
264	6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2004 , 22, 553-553	2.2	13
263	Inflammatory response and oxidative stress during liver resection. <i>PLoS ONE</i> , 2017 , 12, e0185685	3.7	13
262	IDO1 Paneth cells promote immune escape of colorectal cancer. <i>Communications Biology</i> , 2020 , 3, 252	6.7	13
261	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). <i>European Journal of Cancer</i> , 2020 , 132, 43-52	7.5	13
260	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology, The</i> , 2021 , 22, e18-e28	21.7	13
259	Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. <i>European Journal of Cancer</i> , 2020 , 127, 12-20	7.5	12
258	Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?. <i>Current Oncology Reports</i> , 2012 , 14, 35-43	6.3	12
257	Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. <i>Neoplasia</i> , 2011 , 13, 980-90	6.4	12
256	Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 7828-34	12.9	12
255	4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer [First results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24). <i>European Journal of Cancer</i> , 2020 , 132, 43-52	1.6	12
254	Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. Liver Transplant Oncology Group. <i>Journal of Hepatology</i> , 1998 , 28, 497-503	13.4	12
253	Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma. <i>European Journal of Cancer</i> , 2008 , 44, 866-75	7.5	12

252	Management of bone loss induced by aromatase inhibitors. <i>Cancer Investigation</i> , 2006 , 24, 328-30	2.1	12
251	. <i>Annals of Surgery</i> , 2003 , 237, 556-564	7.8	12
250	Intraductal papillary-mucinous adenoma associated with unusual focal fibromatosis: a "postoperative" stromal nodule. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002 , 441, 308-11	5.1	12
249	Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. <i>Anti-Cancer Drugs</i> , 2005 , 16, 441-5	2.4	12
248	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 508-508	2.2	12
247	Heat treatment of hepatocellular carcinoma cells: increased levels of heat shock proteins 70 and 90 correlate with cellular necrosis. <i>Anticancer Research</i> , 2001 , 21, 295-300	2.3	12
246	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. <i>Annals of Oncology</i> , 2019 , 30, 567-574	10.3	11
245	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019 , 21, 39	8.3	11
244	Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer. <i>Breast Care</i> , 2010 , 5, 158-162	2.4	11
243	Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?. <i>Clinical Breast Cancer</i> , 2009 , 9 Suppl 1, S18-27	3	11
242	Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy. <i>Journal of Immunotherapy</i> , 2009 , 32, 638-54	5	11
241	Novel strategies in oncoplastic surgery for breast cancer: immediate partial reconstruction of breast defects. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2007 , 39, 330-339	0.9	11
240	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2021 , JCO2102554	2.2	11
239	Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation. <i>Transplantation Proceedings</i> , 1991 , 23, 2269-71	1.1	11
238	Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study 2015 ,		11
237	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 679-692	5.4	10
236	Distal gastrectomy in pancreaticoduodenectomy is associated with accelerated gastric emptying, enhanced postprandial release of GLP-1, and improved insulin sensitivity. <i>Journal of Gastrointestinal Surgery</i> , 2014 , 18, 52-9	3.3	10
235	Treatment of Bone Metastases in Patients with Advanced Breast Cancer. <i>Breast Care</i> , 2012 , 7, 92-98	2.4	10

234	The location of small tumor deposits in the SLN predicts Non-SLN macrometastases in breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2008 , 34, 857-862	3.6	10
233	Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo 2004 , 24, 609		10
232	Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity?. <i>Breast Cancer Research and Treatment</i> , 1995 , 34, 213-9	4.4	10
231	Abstract S4-3: The EndoPredict score identifies late distant metastases in ER+/HER2- breast cancer patients 2012 ,		10
230	Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 533-533	2.2	10
229	Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. <i>Annals of Oncology</i> , 2019 , 30, 109-114	10.3	10
228	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018 , 24, 3079-3086	12.9	9
227	A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports. <i>Clinical Journal of Oncology Nursing</i> , 2016 , 20, 175-80	1.1	9
226	Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. <i>World Journal of Surgery</i> , 2014 , 38, 456-62	3.3	9
225	Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. <i>Clinical Breast Cancer</i> , 2010 , 10, 267-74	3	9
224	Breast cancer chemoprevention - a vision not yet realized. <i>European Journal of Cancer Care</i> , 2009 , 18, 438-46	2.4	9
223	Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group. <i>European Journal of Cancer</i> , 1998 , 34, 66-70	7.5	9
222	Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. <i>Transplant International</i> , 1992 , 5, S116-S120	3	9
221	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 559-559	2.2	9
220	Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. <i>Anticancer Research</i> , 2017 , 37, 2683-2691	2.3	9
219	Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Positive Trial. <i>BMC Cancer</i> , 2020 , 20, 392	4.8	8
218	Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 18	5.4	8
217	Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study. <i>Onkologie</i> , 2010 , 33, 360-8		8

216	The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 115, 373-80	4.4	8
215	Dosing of zoledronic acid throughout the treatment continuum in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 79, 175-88	7	8
214	The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74 Suppl 1, S2-6	7	8
213	Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and function of dendritic cells. <i>Clinica Chimica Acta</i> , 2006 , 364, 139-47	6.2	8
212	Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene. <i>Langenbecks Archives of Surgery</i> , 2003 , 388, 3-8	3.4	8
211	Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 512-512	2.2	8
210	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2021 , 385, 395-405	59.2	8
209	Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. <i>Anticancer Research</i> , 2000 , 20, 4599-604	2.3	8
208	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTO Trial. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	7
207	The 3-60 criteria challenge established predictors of postoperative mortality and enable timely therapeutic intervention after liver resection. <i>Hepatobiliary Surgery and Nutrition</i> , 2019 , 8, 111-124	2.1	7
206	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEP AUT. <i>Breast</i> , 2020 , 50, 64-70	3.6	7
205	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. <i>Breast Care</i> , 2014 , 9, 344-8	2.4	7
204	Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer. <i>Breast Care</i> , 2012 , 7, 61-66	2.4	7
203	Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. <i>Anti-Cancer Drugs</i> , 2001 , 12, 209-12	2.4	7
202	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.. <i>Lancet Oncology</i> , 2022 ,	21.7	7
201	OKT3 immunoprophylaxis in human liver transplantation. <i>Transplantation Proceedings</i> , 1989 , 21, 2253-4	1.1	7
200	Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 520-520	2.2	7
199	SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 503-503	2.2	7

- 198 Gastrointestinal autonomic nerve tumors: a surgical point of view. *World Journal of Gastroenterology*, **2004**, 10, 2447-51 5.6 7
- 197 Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. *Cancer*, **2020**, 126, 1175-1182 6.4 7
- 196 Delta albumin is a better prognostic marker for complications following laparoscopic intestinal resection for Crohn's disease than albumin alone - A retrospective cohort study. *PLoS ONE*, **2018**, 13, e0206911 3.7 7
- 195 The evolving role of zoledronic acid in early breast cancer. *OncoTargets and Therapy*, **2009**, 2, 95-104 4.4 6
- 194 Adjuvant bisphosphonates: a new standard of care?. *Current Opinion in Oncology*, **2012**, 24, 635-42 4.2 6
- 193 Pancreatic transplantation with venous portal drainage. *Lancet, The*, **1989**, 2, 988 4.0 6
- 192 Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. **2009**, 6
- 191 Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy **2018**, 6
- 190 Abstract S2-07: cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy-based regimens **2016**, 6
- 189 Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).. *Journal of Clinical Oncology*, **2010**, 28, 530-530 2.2 6
- 188 Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.. *Journal of Clinical Oncology*, **2013**, 31, 506-506 2.2 6
- 187 Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.. *Journal of Clinical Oncology*, **2015**, 33, 504-504 2.2 6
- 186 Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. *Acta Oncologica*, **2020**, 59, 75-81 3.2 6
- 185 PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. *British Journal of Surgery*, **2021**, 108, 308-314 5.3 6
- 184 Denosumab and fracture risk in women with breast cancer - Author's reply. *Lancet, The*, **2015**, 386, 2057-2058 4.0 5
- 183 The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer. *Current Breast Cancer Reports*, **2014**, 6, 59-70 0.8 5
- 182 Breast Cancer Is Our Global Responsibility. *Breast Care*, **2015**, 10, 360 2.4 5
- 181 CDK4/6 inhibitors in luminal breast cancer. *Lancet Oncology, The*, **2015**, 16, 2-3 21.7 5

180	Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14. <i>Breast Journal</i> , 2011 , 17, 230-8	1.2	5
179	Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 123-36	5.4	5
178	Tumor recurrence after oLTX. <i>Transplant International</i> , 1996 , 9, S151-S154	3	5
177	Abstract P4-22-20: Efficacy and safety of everolimus plus exemestane in HR+, HER2-advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT 2017 ,		5
176	Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1008-1008	2.2	5
175	The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2017-2024	3.1	5
174	A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. <i>Supportive Care in Cancer</i> , 2018 , 26, 1345-1352	3.9	5
173	Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. <i>Clinical Breast Cancer</i> , 2015 , 15, 505-11	3	4
172	Sized Influences Nodal Status in Women Aged #70 with Endocrine Responsive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 555-556	3.1	4
171	Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts. <i>Breast Disease</i> , 2011 , 33, 71-81	1.6	4
170	Bisphosphonates as adjuvant therapy for breast cancer. <i>Current Breast Cancer Reports</i> , 2009 , 1, 54-63	0.8	4
169	Anticancer activity of bisphosphonates in breast cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012 , 12, 114-22	2.2	4
168	Abgeschlossene und derzeit laufende adjuvante Therapieprotokolle bei Patientinnen mit operablem Mammakarzinom (II). <i>Acta Chirurgica Austriaca</i> , 1997 , 29, 62-67		4
167	Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 859-70	7.4	4
166	Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells 2003 , 22, 1397		4
165	Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model. <i>Oncology Reports</i> , 2004 , 12, 495	3.5	4
164	Preoperative second-line chemotherapy induces objective responses in primary breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2005 , 117, 48-52	2.3	4
163	Kann man einer hochselektionierten Patientinnengruppe nach brusterhaltender Therapie wegen Mammakarzinoms die postoperative Nachbestrahlung ersparen?. <i>Acta Chirurgica Austriaca</i> , 1995 , 27, 269-273		4

162	Neoadjuvant Chemotherapy Enables Breast-Conserving Surgery in Patients with Very Large Breast Cancers: Preliminary Results. <i>Oncology Research and Treatment</i> , 1996 , 19, 242-246	2.8	4
161	Impact of donor cause of death on renal graft function--a multivariate analysis of 1545 kidney transplants. <i>Transplantation Proceedings</i> , 1993 , 25, 3102-3	1.1	4
160	What do intensive care unit personnel think about organ donation? Opinion poll amongst transplant centers. <i>Transplantation Proceedings</i> , 1993 , 25, 3122-3	1.1	4
159	Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC + Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 257-265		4
158	Abstract S5-05: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer ¶The phase III NATAN study (GBG 36/ABCSG XX) 2013 ,		4
157	BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 125-125	2.2	4
156	Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 561-561	2.2	4
155	Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 529-529	2.2	4
154	Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 577-577	2.2	4
153	ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6. <i>ESMO Open</i> , 2021 , 6, 100228	6	4
152	In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. <i>International Journal of Oncology</i> , 2003 , 22, 651-6	1	4
151	Bevacizumab: no comeback in early breast cancer?. <i>Lancet Oncology, The</i> , 2015 , 16, 1001-1003	21.7	3
150	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5. <i>Clinical Cancer Research</i> , 2020 , 26, 5682-5688	12.9	3
149	Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 87-96	4.4	3
148	Dual inhibition of HER2 in breast cancer treatment. <i>Lancet, The</i> , 2012 , 379, 596-8	40	3
147	253 Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial. <i>European Journal of Cancer</i> , 2012 , 48, S116	7.5	3
146	Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1825-36	3.5	3
145	Breast Cancer: Rank Ligand Inhibition. <i>Breast Care</i> , 2010 , 5, 320-325	2.4	3

144	Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells. <i>Endocrine-Related Cancer</i> , 2009 , 16, 73-83	5.7	3
143	The impact of progesterone receptor in prediction of complete pathological response to preoperative chemotherapy in primary breast cancer patients. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2004 , 36, 41-45	0.9	3
142	Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994 , 120, 314-8	4.9	3
141	Abstract PD01-03: Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer 2010 ,		3
140	Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study 2012 ,		3
139	Abstract P3-11-06: Bevacizumab in combination with docetaxel+trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study 2015 ,		3
138	Abstract OT1-03-21: PALLAS: Palbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer 2016 ,		3
137	Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial 2016 ,		3
136	6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2004 , 22, 553-553	2.2	3
135	Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10501-10501	2.2	3
134	Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 512-512	2.2	3
133	Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 104-104	2.2	3
132	LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS613-TPS613	2.2	3
131	Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. <i>Transplant International</i> , 1992 , 5 Suppl 1, S116-20	3	3
130	A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort. <i>ESMO Open</i> , 2021 , 6, 100006	6	3
129	Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2018 , 50, 160-166	0.9	3
128	Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination. <i>Anticancer Research</i> , 2005 , 25, 4225-30	2.3	3
127	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy.. <i>Breast</i> , 2022 , 63, 123-139	3.6	3

126	Denosumab in early-stage breast cancer - Authors' reply. <i>Lancet Oncology, The</i> , 2019 , 20, 236	21.7	2
125	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 545-555	5.1	2
124	Explained variation in shared frailty models. <i>Statistics in Medicine</i> , 2018 , 37, 1482-1490	2.3	2
123	Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. <i>Annals of Oncology</i> , 2018 , 29, 281-282	10.3	2
122	The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer. <i>Cells</i> , 2019 , 8,	7.9	2
121	HER2-positive breast cancer: a new piece of the puzzle. <i>Lancet Oncology, The</i> , 2014 , 15, 668-9	21.7	2
120	Guidelines: usefulness and limitations. <i>Breast Care</i> , 2013 , 8, 172-3	2.4	2
119	Follow-up after breast cancer diagnosis. <i>Breast Care</i> , 2013 , 8, 457-60	2.4	2
118	Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients. <i>Breast Care</i> , 2010 , 5, 298-304	3.4	2
117	Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio. <i>Breast Care</i> , 2009 , 4, 155-161	2.4	2
116	Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012 , 72, 293-298	2	2
115	P60 Adjuvant radiotherapy has no benefit after primary breast cancer treatment in selected postmenopausal patients. <i>European Journal of Cancer</i> , 1998 , 34, S31	7.5	2
114	Managing aromatase inhibitor-associated bone loss in breast cancer. <i>Women's Health</i> , 2007 , 3, 441-8	3	2
113	Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?. <i>Journal of Immunotherapy</i> , 1999 , 22, 85-9	5	2
112	Platelet disorders in uraemia before and after haemodialysis under the influence of low dose aspirin. <i>Thrombosis Research</i> , 1995 , 80, 225-33	8.2	2
111	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101918	2.2	2
110	Soluble interleukin-2 receptor in liver transplant recipients. <i>Transplantation Proceedings</i> , 1991 , 23, 1417-8.1	8.1	2
109	Abstract PD09-05: Impact of Body Mass Index (BMI) on the Efficacy of Endocrine Therapy in Postmenopausal Breast Cancer Patients [An Analysis of the ABCSG 6 and 6a Trial 2010 ,		2

108	P1-06-26: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer. 2011 ,		2
107	Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 102-102	2.2	2
106	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 99-99	2.2	2
105	The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e11601-e11601	2.2	2
104	BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 152-152	2.2	2
103	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 155-155	2.2	2
102	PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1002-1002	2.2	2
101	The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxel. Health-related quality of life during ongoing	2.2	2
100	Primary operation in synchronous metastasized invasive breast cancer patients: First oncologic outcomes of the prospective randomized phase III ABCSG 28 POSYTIIVE trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 557-557	2.2	2
99	ASAMET: A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1591-TPS1591	2.2	2
98	Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 553-553	2.2	2
97	Effect of neoadjuvant chemotherapy with gemcitabine and docetaxel on 3-year survival and resection rate in previously unresectable locally advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4234-4234	2.2	2
96	Clinical management and resolution of stomatitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 558-558	2.2	2
95	Influence of a Structured Exercise Training on Patients Reported Quality of Life in Colorectal Cancer Patients After Adjuvant Chemotherapy: A Pilot Study. <i>Integrative Cancer Therapies</i> , 2020 , 19, 1534735420938458	3	2
94	Pathological complete remission and long-term outcome-what do we know in 2016?. <i>Lancet Oncology, The</i> , 2016 , 17, 693-694	21.7	2
93	Retroviral targeting of proliferating endothelial cells. <i>Acta Biochimica Polonica</i> , 2005 , 52, 731-5	2	2
92	Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. <i>Breast</i> , 2019 , 46, 101-107	3.6	1
91	Morbidity reduction using the vessel sealing device LigaSure in breast cancer surgery. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2015 , 47, 150-156	0.9	1

90	Targeting bone microenvironment: Clinical implications. <i>Breast</i> , 2015 , 24 Suppl 2, S49-50	3.6	1
89	TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact. <i>Annals of the New York Academy of Sciences</i> , 2018 , 1434, 46-53	6.5	1
88	Modern therapeutic concepts of early breast cancer. <i>Breast Care</i> , 2014 , 9, 85-6	2.4	1
87	Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does not affect mortality and morbidity after pancreatic resection. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2013 , 45, 169-178	0.9	1
86	Closing in on the unknown enemy. <i>Lancet Oncology, The</i> , 2010 , 11, 402-3	21.7	1
85	Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data. <i>Clinical Investigation</i> , 2011 , 1, 97-107		1
84	8th European Breast Cancer Conference (EBCC-8), Vienna, March 21-24, 2012. <i>Breast Care</i> , 2012 , 7, 170-176	17.6	1
83	The evolution of bone-targeted therapies: introduction. <i>Seminars in Oncology</i> , 2010 , 37 Suppl 2, S1	5.5	1
82	Adjuvant Endocrine Therapy in Premenopausal Patients. <i>Breast Care</i> , 2008 , 3, 311-316	2.4	1
81	A Case of Phyllodes Tumor with Focal Transition into Low-Grade Lymphangiosarcoma. <i>Breast Care</i> , 2006 , 1, 391-394	2.4	1
80	Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. <i>Oncology Research and Treatment</i> , 2003 , 26, 115-9	2.8	1
79	The Potential Impact of Tamoxifen in Breast Cancer Prevention. <i>Oncology Research and Treatment</i> , 1993 , 16, 297-303	2.8	1
78	Reasons for 50% reduction in the number of organ donors within 2 years--opinion poll amongst all ICUs of a transplant centre. <i>Transplant International</i> , 1994 , 7 Suppl 1, S668-71	3	1
77	Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 542-542	2.2	1
76	Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 551-551	2.2	1
75	Association of TP53 codon 72 polymorphism with TP53 mutation in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1130-1130	2.2	1
74	T-DM1 in HER2-positive breast cancer brain metastases (BM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 650-650	6.50	1
73	A cross-section study evaluating patients'satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17574-e17574	2.2	1

72	Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2 \square PIK3CA mutant or wild-type, breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS655-TPS655	2.2	1
71	Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 551-551	2.2	1
70	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 117-117	2.2	1
69	Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 538-538	2.2	1
68	Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1050-1050	2.2	1
67	Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 524-524	2.2	1
66	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma		1
65	Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC). <i>Journal of Clinical Oncology</i> , 2009 , 27, 1090-1090	2.2	1
64	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 518-518	2.2	1
63	Editorial comment on 'Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials'. <i>European Journal of Cancer</i> , 2016 , 59, 125-127	7.5	1
62	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. <i>Clinical Cancer Research</i> , 2021 , 27, 5931-5938	12.9	1
61	Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 116-122	7.1	0
60	10 years of ATAC: one question answered, many others unresolved. <i>Lancet Oncology, The</i> , 2010 , 11, 1109-1110	2.1	0
59	Cystic neoplasms of the pancreas: conservative or operative treatment?. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2008 , 40, 220-226	0.9	0
58	Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic.. <i>Lancet Oncology, The</i> , 2022 , 23, 195-197	21.7	0
57	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 553-553	2.2	0
56	Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care. <i>JCO Global Oncology</i> , 2021 , 7, 1513-1521	3.7	0
55	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. <i>British Journal of Cancer</i> , 2021 , 124, 1795-1802	8.7	0

54	Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05). <i>Cancer Research</i> , 2022 , 82, P4-10-01-P4-10-01	10.1	0
53	Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.. <i>ESMO Open</i> , 2022 , 7, 100426	6	0
52	The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer - A prospective, controlled, single-center study. <i>International Journal of Surgery</i> , 2022 , 106694	7.5	0
51	PG 4.03 Targeting bone microenvironment: clinical implications. <i>Breast</i> , 2015 , 24, S8-S9	3.6	
50	Reply to the letter to the editor 'duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients' by Fouad et al. <i>Annals of Oncology</i> , 2015 , 26, 1799-800	10.3	
49	Bone metastases, clinical trials II: zoledronic acid and denosumab in the prevention of bone metastases 2015 , 685-689		
48	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016 , 9, 70-75	0.3	
47	Interview: Aspects of modern breast cancer management: a surgeon's tale. <i>Breast Cancer Management</i> , 2014 , 3, 139-143	0.7	
46	4th Austrian pancreas day: a summary of the surgical management of exocrine pancreatic neoplasms. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2013 , 45, 277-281	0.9	
45	0138 ABCSG-16/SALSA: Prospective, open, randomised, multicentre phase III study to assess extended adjuvant treatment with 2 or 5 years' anastrozole in postmenopausal women with endocrine-responsive early breast cancer after 5 years of initial adjuvant endocrine therapy. <i>Breast</i> , 2009 , 18, 653	3.6	
44	To measure the unmeasurable. <i>World Journal of Surgery</i> , 2009 , 33, 52-3	3.3	
43	Adjuvant Chemotherapy of Breast Cancer. <i>Breast Care</i> , 2009 , 4, 339-341	2.4	
42	In Reply to Dr. Dizdar et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, 1651	4	
41	Breast reconstruction - A view from surgical oncology. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2007 , 39, 295-298	0.9	
40	(Neo-)adjuvant chemotherapy in breast cancer - Trials, errors and new rationales from the SABCS 2007. <i>Memo - Magazine of European Medical Oncology</i> , 2008 , 1, 23-26	0.3	
39	The Endocrine Origin and Different Characters of Breast Cancers - Recent Research on Hormone Receptors and Endocrine Treatment*. <i>Breast Care</i> , 2006 , 1, 124-128	2.4	
38	Breast Cancer Chemoprevention - Not yet There. <i>Breast Care</i> , 2006 , 1, 295-296	2.4	
37	Future Directions in the Treatment of Breast Cancer - Cellular Interventions Using Dendritic Cells. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 119-123	4.4	

- 36 Phase-II Trial Using Gemcitabine as Monochemotherapy in Patients with Metastasized Pancreatic Carcinoma. *European Surgery - Acta Chirurgica Austriaca*, **2003**, 35, 342-343 0.9
- 35 Prognostic relevance of three histological grading methods in breast cancer **2001**, 19, 1271
- 34 Die axilläre Lymphknotendisektion in der Therapie des Mammakarzinoms. *European Surgery - Acta Chirurgica Austriaca*, **2000**, 32, 119-123 0.9
- 33 Indikationsstellung und Technik der Brusterhaltenden Operation 61-79
- 32 Operative Taktik und Technik nach Präoperativer Chemotherapie 125-136
- 31 LM02-trial perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases.. *Journal of Clinical Oncology*, **2020**, 38, e16046-e16046 2.2
- 30 Differential effects of epirubicin and docetaxel on the immune system in patients with breast cancer (BC).. *Journal of Clinical Oncology*, **2020**, 38, 588-588 2.2
- 29 Chirurgische Probleme der Lebertransplantation. *Intensivmedizinisches Seminar*, **1989**, 117-123
- 28 Cadaveric kidney donation beyond the age of 60 years--a comparative analysis of 1180 grafts from different donor age groups. *Transplant International*, **1992**, 5 Suppl 1, S47-50 3
- 27 Die Chirurgie des Mammacarcinoms. *Onkologie Heute*, **1999**, 27-37
- 26 Experimentelle Therapie von Lebermetastasen. *Onkologie Heute*, **1999**, 167-174
- 25 Prognostic impact of breast cancer (BC) subtype in elderly patients.. *Journal of Clinical Oncology*, **2015**, 33, e20536-e20536 2.2
- 24 Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTO trial.. *Journal of Clinical Oncology*, **2016**, 34, 604-604 2.2
- 23 Adjuvant Treatment with Bone-Targeting Agents (Bisphosphonates and Anti-RANK-Ligand Antibody) **2017**, 593-598
- 22 Primary surgery versus no surgery in synchronous metastatic breast cancer: Patient-reported outcomes of the ABCSG 28 Positive trial.. *Journal of Clinical Oncology*, **2017**, 35, 1074-1074 2.2
- 21 Independent validation of stromal uPA in archived tumor samples from the prospectively randomized ABCSG8 trial to provide level 1b evidence for a prognostic value of uPA immunohistochemistry in endocrine-treated postmenopausal breast cancer patients.. *Journal of Clinical Oncology*, **2017**, 35, 536-536 2.2
- 20 High accumulation of metformin in colonic tissue of subjects with diabetes or metabolic syndrome.. *Journal of Clinical Oncology*, **2017**, 35, 1557-1557 2.2
- 19 Incomplete surgical resection of DCIS results in activation of HER-2 in residual breast cancer cells. *Journal of Clinical Oncology*, **2009**, 27, e22035-e22035 2.2

18	Quality of life in patients with pancreatic cancer during neoadjuvant chemotherapy using gemcitabine and bevacizumab: A pilot study.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 330-330	2.2
17	BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 539-539	2.2
16	Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 514-514	2.2
15	BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 540-540 ^{2,2}	2.2
14	Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 557-557	2.2
13	Low HER2-expression to predict impaired activity of endocrine therapy in patients with estrogen-receptor (ER) positive metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 573-573	2.2
12	A cross-section questionnaire to evaluate patients' satisfaction with totally implanted access ports (Port-a-Cath; PAC) and analysis of PAC-related complications at a tertiary care center.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20693-e20693	2.2
11	BRCA-1 promotor methylation as predictor of benefit from adjuvant CMF in triple-negative breast cancer not responsive to taxane-based neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 148-148	2.2
10	Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 151-151	2.2
9	Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). <i>Breast Care</i> , 1-9	2.4
8	Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. <i>Cancer Research</i> , 2022 , 82, P5-13-36-P5-13-36	10.1
7	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. <i>Cancer Research</i> , 2022 , 82, GS1-07-GS1-07	10.1
6	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. <i>Cancer Research</i> , 2022 , 82, PD2-04-PD2-04	10.1
5	Abstract P1-02-07: Accuracy and predictive value of resection margin assessment by intraoperative frozen section after neoadjuvant therapy: An analysis of the ABCSG 24 and 34 trials. <i>Cancer Research</i> , 2022 , 82, P1-02-07-P1-02-07	10.1
4	Abstract DEB1-1: Pro - RxPONDER: Was it all OFS?. <i>Cancer Research</i> , 2022 , 82, DEB1-1-DEB1-1	10.1
3	Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. <i>Cancer Research</i> , 2022 , 82, P4-06-08-P4-06-08	10.1
2	Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial. <i>Cancer Research</i> , 2022 , 82, P4-12-01-P4-12-01	10.1
1	The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997 , 123, 317-324	4.9

